Gov. Mark Gordon sings a ban on the use of abortion pills in Wyoming; a new study shows that Affordable Care Act has reduced racial disparities in health care; California Gov. Gavin Newsom announces a contract to make affordable insulin.
Wyoming Governor Signs Proposed Abortion Pill Ban
Republican Gov. Mark Gordon signed into law a ban on the use of abortion pills in Wyoming, with a separate measure allowing abortion restriction to become law without his signature, according to The Associated Press. This ban would not only prohibit the use of abortion pills in the state starting in July, but also condone legislation banning all abortions. There is no implementation date yet for the all-encompassing abortion ban; abortion remains legal in Wyoming up until viability, or until the fetus would be able to survive outside of the womb.
ACA Reduces Racial Disparities in Health Care
A new report by The Commonwealth Fund shows expanded health insurance under the Affordable Care Act (ACA) reduced racial disparities in health care, according to CBS News. Since its implementation in 2013 allowing Medicaid expansion, the ACA has increased health insurance eligibility among minority individuals and their families. According to the report, "The coverage gap between Black and White adults dropped from 9.9 to 5.3 percentage points, while the gap between Hispanic and White adults dropped from 25.7 to 16.3 points,” according to the study.
California Enters Contract to Make Its Own Affordable Insulin
Gov. Gavin Newsom has announced a contract with nonprofit drugmaker Civica Rx to create California’s own line of affordable insulin for individuals living in the state, according to NPR. The contract will cover 3 forms of insulin: glargine, lispro, and aspart, which are expected to be used interchangeably with other brand name insulins, such as Sanofi’s Lantus, Eli Lilly’s Humalog, and Novo Nordisk’s Novolog, respectively. Once approved by the FDA, California will enter a 10-year contract to create CalRx insulins later this year, with a price tag not to exceed $30 per 10-mL vial.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More